Iovance Biotherapeutics Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
All right. Hello, everyone. Thanks so much for joining us on Day 2 of Oppenheimer's 32nd Annual Healthcare Conference. My name is Mark Breidenbach, and my research team covers emerging biotechnology for OpCo.
The next presenting company is Iovance, which is developing a pipeline of tumor-infiltrating lymphocyte, or TIL, therapies for cancer, which we think are especially noteworthy because of their proven efficacy in solid tumors. Joining us for the discussion is the company's COO, Igor Bilinsky. We'll try and leave a few minutes at least at the end for Q&A. (Operator Instructions)
So with that said, let's dive right into the presentation. Igor, I'm going to hand over the mic to you.
Thank you, Mark, and good afternoon, everyone. Great to be here today, and thanks for the opportunity to share Iovance's progress. We are a publicly listed company, and I'll be making forward
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |